

Project Name	Coronavirus Resilience Preparedness		
Project Lead	Jim Miller Director Procurement, Commissioning & Facilities		
Period Covered	3rd-6th February 2020	Report Date	6 th February 2020

Overall RAG Status	
Amber	Activity is underway across a number of areas, including pandemic product availability, clinical waste protocols, potential infrastructure demands. Agreement with SG resilience team for co-ordination baseline meeting 11 th February.

Highlights	
Scope	
This update covers activity across:	
<ul style="list-style-type: none"> • Pandemic product stockholding • Emergency planning medicine • Clinical waste protocols • Infrastructure/facilities requests • Other relevant areas, e.g. HPS interdependencies 	
Progress achieved:	
Pandemic product stockholding	
<ol style="list-style-type: none"> 1. Internal NP team established. Lead Gordon Beattie 2. Updated stock and product status detail provided to Scottish Government resilience unit (SGR) 3. Access and call-off protocols and SOPs confirmed 4. 4 nations engagement on additional in-bound stock 5. Participation in 4 NHSE revalidation of expired date product 	
Emergency planning medicine	
<ol style="list-style-type: none"> 1. Confirmed NHSE protocols for access and call-off. Lead Lindsay McClure 	
Clinical waste protocols	
<ol style="list-style-type: none"> 1. Agreement with HPS on clinical waste protocols in the event of live incident 	
Infrastructure/facilities requests	
<ol style="list-style-type: none"> 1. Early assessment and responses to requests on accommodation availability/options 	
Other	
<ol style="list-style-type: none"> 1. NHSE approach on HCID capacity 	

Next tasks to be completed:

- Resilience co-ordination meeting with SGR, HPS and PCF February 11th
- Confirmation of inbound product levels
- Confirmation of revalidation status for expired product
- Agree HPS/PCF information sharing protocols

Communications:

1. Note to HoPs regarding ordering process and access to stock levels

Key Issues:

1. Large volume of out of date stock of product line (FFP3). See table 1 at end of document. Assuming revalidation agreed reworking activity will be significant.
2. Immediate increase in workload levels for key personnel

Key Risks:

1. Potential wider disruption to supply chain, either from China based production impact, or wider demand impacts
2. Unknown clinical/impact algorithm and potential impact on stock levels
3. Clinical waste processes still in contingency

FFP3 Status (Pandemic)			
Current Holding	1,600,000		2019 expired
Inbound due 7/2		100,000	June 2020 expiry
Inbound due 29/2		560,000	New product

Notes:

1. Almost all current stock has date expired, (having been previously revalidated 2016).
2. NHSE are undertaking batch testing to obtain revalidation approval, which will apply to similar batches for NHSS stock (results expected by end February)